keyword
MENU ▼
Read by QxMD icon Read
search

Non Clear Cell RCC

keyword
https://www.readbyqxmd.com/read/29317731/renal-capsular-invasion-is-a-prognostic-biomarker-in-localized-clear-cell-renal-cell-carcinoma
#1
U-Syn Ha, Kyu Won Lee, Jin-Hyung Jung, Seok-Soo Byun, Cheol Kwak, Jinsoo Chung, Eu Chang Hwang, Yong-June Kim, Tae Gyun Kwon, Seok Ho Kang, Sung-Hoo Hong
Renal capsular invasion (RCI) and lymphovascular invasion (LVI) are potential prognostic factors of significance in renal cell carcinoma (RCC). We evaluated the independent prognostic implications of RCI and LVI in localized clear cell RCC based on a large multi-institutional cohort. 6, 849 patients who had undergone radical or partial nephrectomy for RCC were included. Associations between recurrence and RCI or LVI were analyzed by constructing statistical models that combined Cox proportional hazard regression and propensity score matching...
January 9, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29291011/transferrin-receptor-1-upregulation-in-primary-tumor-and-downregulation-in-benign-kidney-is-associated-with-progression-and-mortality-in-renal-cell-carcinoma-patients
#2
Christopher J Greene, Kristopher Attwood, Nitika J Sharma, Kenneth W Gross, Gary J Smith, Bo Xu, Eric C Kauffman
The central dysregulated pathway of clear cell (cc) renal cell carcinoma (RCC), the von Hippel Lindau/hypoxia inducible factor-α axis, is a key regulator of intracellular iron levels, however the role of iron uptake in human RCC tumorigenesis and progression remains unknown. We conducted a thorough, large-scale investigation of the expression and prognostic significance of the primary iron uptake protein, transferrin receptor 1 (TfR1/CD71/TFRC), in RCC patients. TfR1 immunohistochemistry was performed in over 1500 cores from 574 renal cell tumor patient tissues (primary tumors, matched benign kidneys, metastases) and non-neoplastic tissues from 36 different body sites...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29282004/pathologic-analysis-of-non-neoplastic-parenchyma-in-renal-cell-carcinoma-a-comprehensive-observation-in-radical-nephrectomy-specimens
#3
Xun Wang, Qiang Liu, Wen Kong, Jiwei Huang, Yonghui Chen, Yiran Huang, Jin Zhang
BACKGROUND: This study provides a comprehensive examination of the histological features of non-neoplastic parenchyma in renal cell carcinoma (RCC). We prospectively collected radical nephrectomy (RN) specimens, to analyze the histological changes within peritumoral and distant parenchyma. METHODS: Data of patients who underwent RN and had no known history of diabetes, hypertension, hyperlipidemia, or chronic kidney disease etc., were prospectively collected. Tumor pseudo-capsule (PC), and parenchyma within 2 cm from tumor margin, were pathologically assessed...
December 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29277781/expression-and-distribution-of-galectin-3-in-chromophobe-and-papillary-carcinomas
#4
Andreea Cioca, Diana Muntean, Catalina Bungardean, Marius Raica, Anca Maria Cimpean
BACKGROUND/AIM: Probably due to their low occurrence, chromophobe and papillary renal cell carcinomas are less well characterized and, currently, there are no reliable prognostic markers for this group of patients. Moreover, the optimal therapy for patients with non-clear renal cell carcinoma (RCC) is unknown yet. Although elevated levels of Galectin-3 (Gal-3) were associated with poor prognosis in conventional RCC, the impact of this protein on carcinogenesis of chromophobe and papillary entities has not been previously described...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29250194/rho-gdp-dissociation-inhibitor-%C3%AE-in-renal-cell-carcinoma
#5
Christoph-Alexander von Klot, Natalia Dubrowinskaja, Inga Peters, Jörg Hennenlotter, Axel S Merseburger, Arnulf Stenzl, Markus A Kuczyk, Jürgen Serth
Rho GDP dissociation inhibitor-β (ARHGDIB) is an important mediator of cell signaling. The expression of ARHGDIB is associated with tumor growth and metastasis in a variety of non-genitourinary cancers; however, the role of ARHGDIB in renal cell carcinoma (RCC) has not yet been evaluated. In the present study, tissue samples from 105 patients undergoing surgery for RCC were obtained. The expression levels of ARHGDIB mRNA in normal kidney tissues and in corresponding cancer tissues were analyzed by reverse transcription-quantitative polymerase chain reaction...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29184790/factors-associated-with-acutely-elevated-serum-creatinine-following-radical-tumour-nephrectomy-the-correlates-of-kidney-dysfunction-tumour-nephrectomy-database-study
#6
Robert J Ellis, Sharon J Del Vecchio, Keng Lim Ng, Goce Dimeski, Elaine M Pascoe, Carmel M Hawley, David W Johnson, David A Vesey, Jeff S Coombes, Christudas Morais, Ross S Francis, Simon T Wood, Glenda C Gobe
Background: To identify factors associated with acutely elevated serum creatinine (SCr) within 7 days of radical tumour nephrectomy. Methods: The study population consisted of 130 consecutive patients managed for renal tumours. The primary outcome was acute kidney injury (AKI) (defined as SCr increase ≥50% above baseline), assessed using multivariable logistic regression analysis. The secondary outcome was SCr percentage increase, assessed using multivariable linear regression analysis...
October 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29165391/micrornas-associated-with-von-hippel-lindau-pathway-in-renal-cell-carcinoma-a-comprehensive-review
#7
REVIEW
Lisa-Maria Schanza, Maximilian Seles, Michael Stotz, Johannes Fosselteder, Georg C Hutterer, Martin Pichler, Verena Stiegelbauer
Renal cell carcinoma (RCC) are the most common renal neoplasia and can be divided into three main histologic subtypes, among which clear cell RCC is by far the most common form of kidney cancer. Despite substantial advances over the last decade in the understanding of RCC biology, surgical treatments, and targeted and immuno-therapies in the metastatic setting, the prognosis for advanced RCC patients remains poor. One of the major problems with RCC treatment strategies is inherent or acquired resistance towards therapeutic agents over time...
November 22, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29148041/fscn1-predicts-survival-and-is-regulated-by-a-pi3k-dependent-mechanism-in-renal-cell-carcinoma
#8
Mengping Zhang, Zhijian Zhao, Xiaolu Duan, Ping Chen, Zhenwei Peng, Huijuan Qiu
While overexpression of FSCN1 is reported in several cancers, the prognostic significance of FSCN1 in renal cell carcinoma (RCC) and the molecular mechanisms involved remain largely unclear. We retrospectively enrolled 194 patients with non-metastatic clear-cell RCC undergoing nephrectomy in our center between 2008 and 2011. FSCN1 expression was assessed by immunohistochemical staining and its association with clinicopathologic features and survival were evaluated. Functional effects of a modulated FSCN1 expression were analyzed with regard to invasion in RCC cell lines and metastasis in vivo...
November 17, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29133143/pathologic-and-clinical-characteristics-of-early-onset-renal-cell-carcinoma
#9
Tyler Clemmensen, Andres Matoso, Tiffany Graham, Win Shun Lai, Soroush Rais-Bahrami, Jennifer Gordetsky
The majority of RCCs occur within the 7th decade of life, uncommonly arising in adults ≤46years. We reviewed the clinicopathologic features of early-onset renal cell carcinoma (RCC) and evaluated the role of immunohistochemistry (IHC) in potentially identifying diagnoses of newly recognized RCC subtypes that may have been previously misclassified. A retrospective review was performed from 2011-2016 for cases of RCC. Early-onset RCC was defined as ≤46years of age. Clinicopathologic findings and hematoxylin and eosin (H&E) slides were reviewed on early-onset RCC patients...
November 10, 2017: Human Pathology
https://www.readbyqxmd.com/read/29056573/noncoding-rna-expression-and-targeted-next-generation-sequencing-distinguish-tubulocystic-renal-cell-carcinoma-tc-rcc-from-other-renal-neoplasms
#10
Charles H Lawrie, María Armesto, Marta Fernandez-Mercado, María Arestín, Lorea Manterola, Ibai Goicoechea, Erika Larrea, María M Caffarel, Angela M Araujo, Carla Sole, Maris Sperga, Isabel Alvarado-Cabrero, Michal Michal, Ondrej Hes, José I López
Tubulocystic renal cell carcinoma (TC-RCC) is a rare recently described renal neoplasm characterized by gross, microscopic, and immunohistochemical differences from other renal tumor types and was recently classified as a distinct entity. However, this distinction remains controversial particularly because some genetic studies suggest a close relationship with papillary RCC (PRCC). The molecular basis of this disease remains largely unexplored. We therefore performed noncoding (nc) RNA/miRNA expression analysis and targeted next-generation sequencing mutational profiling on 13 TC-RCC cases (11 pure, two mixed TC-RCC/PRCC) and compared with other renal neoplasms...
October 19, 2017: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/29050224/secreted-mir-210-3p-as-non-invasive-biomarker-in-clear-cell-renal-cell-carcinoma
#11
Vincenzo Petrozza, Antonio Luigi Pastore, Giovanni Palleschi, Claudia Tito, Natale Porta, Serena Ricci, Chiara Marigliano, Manuela Costantini, Giuseppe Simone, Angelina Di Carlo, Michele Gallucci, Antonio Carbone, Francesco Fazi
The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC). It accounts for 70-80% of all renal malignancies representing the third most common urological cancer after prostate and bladder cancer. The identification of non-invasive biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent a relevant step-forward in ccRCC management. The aim of this study is to evaluate whether specific miRNAs deregulated in ccRCC tissues present altered levels also in urine specimens...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29022072/effect-of-pathological-high-risk-features-on-cancer-specific-mortality-in-non-metastatic-clear-cell-renal-cell-carcinoma-a-tool-for-optimizing-patient-selection-for-adjuvant-therapy
#12
Marco Bandini, Ariane Smith, Emanuele Zaffuto, Raisa S Pompe, Michele Marchioni, Umberto Capitanio, Felix K Chun, Anil B Kapoor, Shahrokh F Shariat, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz
PURPOSE: Adjuvant therapies for non-metastatic renal cell carcinoma (nmRCC) are being tested to improve outcomes in patients with high-risk (hR) nmRCC. The objective of the current study is to test the ability of three hR features to identify patients who are at the highest risk of cancer-specific mortality (CSM) after partial or radical nephrectomy. METHODS: Within the Surveillance Epidemiology and End Results (SEER) database (1988-2013), we identified 23,632 nm "clear cell" RCC partial or radical nephrectomy patients with hR features: Fuhrman grade (FG) 3 or 4 or pathological classifications T3a or T3b or lymph node invasion (LNI), or combination of these...
October 11, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28986088/expression-of-tyrosine-kinase-receptor-axl-is-associated-with-worse-outcome-of-metastatic-renal-cell-carcinomas-treated-with-sunitinib
#13
Luís Eduardo Zucca, Mariana Andozia Morini Matushita, Renato José da Silva Oliveira, Cristovam Scapulatempo-Neto, Marcos Alves de Lima, Guilherme Gomes Ribeiro, Cristiano Ribeiro Viana, Flavio Mavignier Cárcano, Rui Manuel Reis
BACKGROUND: Renal cell carcinoma (RCC) represents 2%-3% of all cancers of the Western countries. Currently, sunitinib, a receptor tyrosine kinase inhibitor, particularly of PDGF and VEGF receptors, is the first-line therapy for metastatic RCC (mRCC), with significant improvement in clinical outcome. However, there is a lack of predictive biomarkers of sunitinib response. Recently, others and our group suggested that the receptor tyrosine kinase AXL may modify the response to sunitinib...
October 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28975890/identification-and-validation-of-novel-prognostic-markers-in-renal-cell-carcinoma
#14
Maj Rabjerg
Kidney cancer (Renal Cell Carcinoma (RCC)) is one of the most deadly malignancies due to frequent late diagnosis and poor treatment options. Histologically, RCC embraces a wide variety of different subtypes with the clear cell variant (ccRCC) being the most common, accounting for 75-90% of all RCCs. At present, the surveillance protocols for follow-up of RCC patients after radical nephrectomy are based on the American Joint Committee on Cancers (AJCC) pathological tumor-node-metastasis (TNM) classification system...
October 2017: Danish Medical Journal
https://www.readbyqxmd.com/read/28974261/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-57-66-edited-by-chinese-journal-of-cancer
#15
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 10 more questions are presented as followed. Question 57. What are the major stresses that drive the formation, progression, and metastasis of a cancer? Question 58. What is the mechanism responsible for altering an acidic intracellular pH and a basic extracellular pH in normal tissue cells to a basic intracellular pH and an acidic extracellular pH in cancer cells, a fundamental and yet largely ignored phenomenon? Question 59...
October 3, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28952411/clinical-development-of-mtor-inhibitors-for-renal-cancer
#16
REVIEW
Michele Ghidini, Fausto Petrelli, Antonio Ghidini, Gianluca Tomasello, Jens Claus Hahne, Rodolfo Passalacqua, Sandro Barni
Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. In the last 10 years, clinical trials have established multitargeted tyrosine kinase inhibitors (TKIs) as the standard first-line treatment in patients with metastatic disease. Multiple agents are now available for treatment in subsequent lines.The mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus alone or with lenvatinib) are among the most effective options. Areas covered: This paper provides a complete and updated overview on mTOR inhibitors for the treatment of advanced RCC...
November 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28951115/characterization-and-impact-of-tert-promoter-region-mutations-on-clinical-outcome-in-renal-cell-carcinoma
#17
Jozefina Casuscelli, Maria F Becerra, Brandon J Manley, Emily C Zabor, Ed Reznik, Almedina Redzematovic, Maria E Arcila, Daniel M Tennenbaum, Mazyar Ghanaat, Mahyar Kashan, Christian G Stief, Maria Carlo, Martin H Voss, Darren R Feldman, Robert J Motzer, Yingbei Chen, Victor E Reuter, Jonathan A Coleman, Paul Russo, James J Hsieh, Abraham Ari Hakimi
BACKGROUND: Mutations in the promoter region of the TERT gene have been detected in a variety of cancers. These mutations can potentially lead to unlimited cell divisions and result in poor clinical prognosis. OBJECTIVE: To determine the role and relevance of TERT promoter region mutations in both clear cell (ccRCC) and non-clear cell (nccRCC) renal cell carcinoma using ultra-deep and whole-genome sequencing methods on primary tumor samples. DESIGN, SETTING, AND PARTICIPANTS: DNA from 281 kidney tumors (147 ccRCC and 134 nccRCC) was sequenced between 2013 and 2015, and clinical outcomes for these patients from a single institution were retrospectively analyzed...
September 23, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28936542/efficacy-of-percutaneous-radiofrequency-ablation-may-vary-with-clear-cell-renal-cell-cancer-histologic-subtype
#18
Timothy McClure, Allan Pantuck, James Sayer, Steven Raman
PURPOSE: The purpose of the study is to determine if clear cell renal cell cancer (RCC) subtype predicts efficacy in percutaneous radiofrequency (RF) ablation of RCC. METHODS AND MATERIALS: Patients who underwent percutaneous RF ablation for histologically proven RCC subtypes were retrospectively reviewed. Group comparisons were done using univariate and multivariate logistic regression analysis to determine factors impacting primary, secondary, and total technique effectiveness...
September 21, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28934212/outcome-of-papillary-versus-clear-cell-renal-cell-carcinoma-varies-significantly-in-non-metastatic-disease
#19
MULTICENTER STUDY
Nina Wagener, Dominic Edelmann, Axel Benner, Richard Zigeuner, Hendrik Borgmann, Ingmar Wolff, Laura M Krabbe, Mireia Musquera, Paolo Dell'Oglio, Umberto Capitanio, Tobias Klatte, Luca Cindolo, Matthias May, Sabine D Brookman-May
Renal cell carcinoma (RCC) comprises a heterogenous group of tumors. Traditionally, papillary RCC (pRCC) is associated with a favorable outcome compared to clear cell RCC (ccRCC), while other series report equivalent or worse prognosis. In this paper we comparatively evaluate outcome of pRCC versus ccRCC in two large multi-institutional databases (cohort study), including distribution of pRCC subtypes 1 and 2. Retrospective data of 1,943 surgically treated pRCC patients from 17 European/ North American centers between 1984-2015 were compared to 5,600 ccRCC patients from a database comprising 11 European/ North American centers (1984-2011)...
2017: PloS One
https://www.readbyqxmd.com/read/28928816/analysis-of-long-non-coding-rna-expression-profiles-in-clear-cell-renal-cell-carcinoma
#20
Fei Yan Yang, Yan Wang, Jian Guo Wu, Shao Li Song, Gang Huang, Wei Min Xi, Li Ling Tan, Jian Wang, Qing Cao
To investigate the expression patterns of long non-coding RNAs (lncRNAs) in clear cell renal cell carcinoma (ccRCC) and in metastatic renal cell carcinoma (RCC), the present study downloaded three human exon arrays available from the public Gene Expression Omnibus. The probes of the human exon arrays were re-annotated and the probes uniquely mapping to lncRNAs were retained at the gene level. Following the analysis of GSE53757 and GSE46699, which contained paired ccRCC cancer and normal adjacent tissue samples, 32 differentially expressed lncRNAs (adjusted P<0...
September 2017: Oncology Letters
keyword
keyword
104989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"